Send to

Choose Destination
Clin Exp Rheumatol. 2010 Mar-Apr;28(2 Suppl 58):S55-62. Epub 2010 Jun 24.

Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.

Author information

Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.


Pulmonary disease is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Recent well-designed trials in SSc-associated interstitial lung disease (SSc-ILD) have provided important insights regarding outcome measures and trial design. Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Clinical and Experimental Rheumatology
Loading ...
Support Center